NCT05610566招募中不适用
A Prospective, Multicentric Clinical Trial Protocol to Evaluate the Safety and Efficacy of the HighLife Trans-Septal Transcatheter Mitral Valve Replacement System for the Treatment of Moderate-severe or Severe Mitral Regurgitation With Single-arm Objective Performance Criteria
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 110
- 试验地点
- 1
- 主要终点
- All-cause mortality at 12 months
研究概览
简要总结
To observe and evaluate the safety and efficacy of the HighLife Transcatheter Mitral Valve Replacement System in patients with moderate-severe or severe mitral valve regurgitation through a prospective, multicenter clinical trial using objective performance criteria.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients who voluntarily participate and sign the informed consent form and can cooperate with the completion of the entire trial process;
- •Age ≥ 18 years old;
- •Moderate-severe or severe mitral regurgitation (≥3+); Note 1: Patients with ischemic or non-ischemic heart disease induced symptomatic secondary mitral regurgitation as the primary cause must be treated for at least 1 month after optimal guideline medical therapy (GDMT). Echocardiography should be performed 3 months after cardiac resynchronization therapy and 1 month after coronary revascularization to assess the degree of regurgitation.
- •Note 2: For patients with primary mitral regurgitation, the multidisciplinary cardiac team of the research center needs to use a standard scoring system, considering multiple factors such as complications, frailty, and disability, ensuring the enrolled with a high risk of surgery.
- •Patients with New York Heart Association (NYHA) functional ratings are Class II, III, or ambulatory Class IV;
- •Anatomically appropriate for treatment with the HighLife Transcatheter Mitral Valve Replacement System.
排除标准
- •Patients had any stroke/TIA within 30 days;
- •Patients with severe symptomatic bilateral carotid stenosis (>70% stenosis on non-invasive imaging);
- •Patients with active infection requiring antibiotic therapy;
- •Patients with active ulcer or gastrointestinal bleeding within the past 3 months;
- •Patients with history of coagulopathy or refuse future blood transfusion;
- •Patients unable to undergo transesophageal echocardiography (TEE);
- •Patients who are pregnant or breastfeeding, or planning to have children within 12 months;
- •Patients who are unable to adhere to the follow-up schedule and complete the examination;
- •Patients enrolled in other clinical studies and within the follow-up period;
- •Patients with known allergies to device components or contrast agents;
- •Patients unable to receive anticoagulant or antiplatelet therapy;
- •Patients with a life expectancy of less than 12 months due to non-cardiac disease;
- •Patients requiring emergency surgical treatment;
- •Patients scheduled for cardiac surgery within 12 months;
- •Patients with an inappropriate mitral annulus or leaflet size (<30 mm and >45 mm);
- •Patients with moderate or above mitral stenosis;
- •Flail mitral leaflets, or moderate to severe mitral valve prolapse;
- •Patients with severe hepatic or renal insufficiency;
- •Patients with severe calcification of the mitral annulus and/or mitral leaflets;
- •Patients with history of mitral valve surgery or interventional therapy, or left atrial appendage occlusion device;
- •Patients had acute myocardial infarction (MI) (Q-wave MI, or non-Q-wave MI, with CK-MB twice the normal and/or T-MB) within the past 1 month;
- •Patients with untreated symptomatic coronary lesions requiring revascularization;
- •Patients with untreated severe aortic stenosis and severe aortic regurgitation;
- •Patients with aortic valve prosthesis;
- •Patients with severe tricuspid valve lesions requiring surgical intervention;
- •Patients with significant right ventricular dysfunction (such as biliteral lower extremities edema with increased jugular vein pulsation and hepatomegaly;
- •LVEF < 30%; LVEDD > 70 mm;
- •Patients with echocardiographically confirmed intracardiac mass, thrombus or neoplasm;
- •Hypertrophic obstructive cardiomyopathy (HOCM);
- •Patients with active or recent (within 3 months) endocarditis;
- •Patients with definite non-left heart disease induced severe pulmonary hypertension (echocardiographic indication: systolic pulmonary artery pressure (SPAP) > 70 mmHg)
- •Patients with hypotension (systolic blood pressure <90 mmHg) occurring within 7 days or mechanical hemodynamic support.
结局指标
主要结局
All-cause mortality at 12 months
时间窗: 12 months
All-cause mortality
次要结局
- Cardiac function change(30 days, 6 months, 12 months, 2 years, 3 years, 4 years and 5 years)
- Technical success(Immediate after procedure)
- Quality of life of patients(30 days, 6 months, 12 months, 2 years, 3 years, 4 years and 5 years)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
不适用
Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.Mitral Valve RegurgitationNCT03242642Medtronic Cardiovascular1,056
已完成
不适用
HighLife™ Transcatheter Mitral Valve Replacement System StudyMitral Valve RegurgitationMitral Valve InsufficiencyNCT02974881HighLife SAS5
尚未招募
不适用
To Evaluate the Efficacy and Safety of the Transfemoral Mitral Valve Repair System in the Treatment of Patients With Moderately Severe and Severe Functional Mitral Regurgitation(FMR) Who Remained Clinically Symptomatic After Guideline-directed Medical TreatmentMitral Valve InsufficiencyNCT05508438Pan Xiangbin140
已完成
不适用
Transcatheter Mitral Valvuloplasty Pilot StudyMitral Valve InsufficiencyMitral Valve RegurgitationMitral RegurgitationNCT04351984Duk-Woo Park, MD5
撤回
不适用
Feasibility Study of Patients With Severe MR Treated With the Cardiovalve TMVR SystemMitral RegurgitationNCT03714412Cardiovalve Ltd.